Iovance Biotherapeutics Stock Rises Premarket on Positive Trial Data for Cancer Drug
By Adriano Marchese
Iovance Biotherapeutics shares rose after the company received positive data from a clinical trial of its cancer treatment.
Shares traded 11% higher ahead of the morning bell at $2.18.
The biotechnology company, which specializes in cell therapies for cancer, on Monday said that about 26% of patients responded to the lifileucel monotherapy treatment in Phase 2 testing, including two who saw their cancer disappear. The San Carlos, Calif., company said the disease-control rate, or the proportion of patients who had their disease stabilize or improve, was at about 72%.
Iovance said it plans to present more data in 2026 and hopes to progress toward a biologics license application with the Food and Drug Administration next year as well. It aims for a potential launch in the second half of 2027, it said.
Write to Adriano Marchese at adriano.marchese@wsj.com
(END) Dow Jones Newswires
November 03, 2025 09:40 ET (14:40 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States